Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14096644 | 0.84 | MAOA (0.55) | MAOACYP3A4CYP2D6CYP2A6ACHE | |
| SCHEMBL11253029 | 0.84 | MAOA (0.59) | MAOACYP3A4CYP2D6CYP2A6ACHE | |
| SCHEMBL11253468 | 0.84 | MAOA (0.55) | MAOACYP3A4CYP2D6CYP2A6ACHE | |
| SCHEMBL18787936 | 0.81 | CYP3A4 (0.56) | MAOACYP3A4CYP2D6CYP2A6ACHE | |
| SCHEMBL6993046 | 0.78 | MCL1 (0.45) | MAOACYP3A4CYP2D6CYP2A6ACHE | |
| SCHEMBL11317544 | 0.77 | ERAP1 (0.42) | MAOACYP3A4CYP2D6CYP2A6ACHE | |
| SCHEMBL17373028 | 0.75 | MAOA (1.00) | MAOACYP3A4CYP2D6CYP2A6ACHE | |
| SCHEMBL11268588 | 0.75 | KCNA3 (0.46) | MAOACYP3A4CYP2D6CYP2A6ACHE | |
| SCHEMBL30776763 | 0.75 | SRD5A1 (0.64) | MAOACYP3A4CYP2D6CYP1A2KDM4E | |
| Xanthotoxol SCHEMBL499269 | 0.75 | CYP3A4 (0.59) | MAOACYP3A4CYP2D6CYP2A6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4328239-A | 8-Aminoalkylpsoralens | ELDER PHARMACEUTICALS, INC. (US) | 1982-05-04 | — | — | US | claimed |
| EP-1032265-B1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030082510-A1 | Psoralens for pathogen inactivation | CERUS CORPORATION (US) | 2003-05-01 | — | — | US | disclosed |
| US-6455286-B1 | MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN | CERUS CORPORATION | 2002-09-24 | — | — | US | disclosed |
| EP-1032265-A4 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6133460-A | HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID | CERUS CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| EP-1032265-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026476-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
| US-4328239-A | 8-Aminoalkylpsoralens | ELDER PHARMACEUTICALS, INC. (US) | 1982-05-04 | — | — | US | disclosed |
| US-4294822-A | 5-Aminoalkyl-4,4,8-trialkylpsoralens | THOMAS C. ELDER, INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4279922-A | Photosensitizing benzofuranacrylics | THOMAS C. ELDER, INC. (US) | 1981-07-21 | — | — | US | disclosed |
| US-4269851-A | 8-Aminoalkyl-4-alkylpsoralens | THOMAS C. ELDER, INC. (US) | 1981-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082510-A1 | Psoralens for pathogen inactivation | BPGM, XPA, RAD50 | MAOA 2213/4885CYP3A4 544/4885CYP2D6 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.